# Biomason

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomason

- Industry: Materials
- Headquarters: US
- Website: www.biomason.com
- Total disclosed funding: $95M
- Latest round: Series B (Dec 19, 2024)
- Investors on record: 6

## About

Based in the US, Biomason, Inc. operates as a pioneer in biocement production, creating sustainable concrete alternatives through innovative biological processes that sequester carbon and reduce environmental impact.Biomason, Inc. was founded in 2012 and is headquartered in the US. The company specializes in producing biocement, which utilizes natural materials and microorganisms to create high-quality concrete. The founders, Ginger Dosier and Michael Dosier, have a history of innovation in sustainable materials. Recently, Biomason raised USD 30.10 mn in Series B funding on December 19, 2024, from investors including Acorn Innovestments, Novo Holdings, Martin Marietta Materials Inc, Hartree Partners LP, Celesta Capital, and 2150, contributing to a total amount raised of USD 30.10 mn and a current company valuation of USD 170.51 mn.Biomason specializes in the production of biocement, an innovative alternative to traditional Portland cement, which utilizes natural materials and microorganisms to create high-quality concrete. Their core offering involves a biological process where common materials are combined through the action of bacteria to form a calcium carbonate binder. This process not only produces concrete but also sequesters carbon, addressing one of the significant contributors to global carbon emissions. Biomason's biocement products are manufactured at the Biobeton factory in Denmark, a collaboration with IBF, the country's largest precast concrete producer. The company targets markets in North America, Europe, and potentially Asia, serving diverse clients including concrete manufacturers and construction companies focused on sustainable building practices.Biomason's revenue model is centered around partnerships and direct sales to concrete producers who incorporate their biocement technology into their products. Transactions typically occur on a B2B basis, where clients purchase biocement for use in various construction applications, thereby integrating Biomason’s innovative materials into their supply chains. The pricing structure is based on the volume of biocement purchased, allowing clients to scale their orders according to demand. Given the environmental benefits and the growing emphasis on sustainability within the construction industry, Biomason's products are increasingly appealing to builders looking to reduce their carbon footprint. The company's flagship offerings include proprietary biocement formulations tailored for specific applications in precast concrete products.In December 2024, Biomason, Inc. raised USD 30.10 mn in Series B funding to support its initiatives for future growth. The company plans to expand its product line with new biocement formulations aimed at diverse applications in the construction sector. Additionally, Biomason is targeting expansion into Asian markets by 2025, leveraging its innovative approach to meet the increasing demand for sustainable construction materials. The recent funding round will facilitate the development of these new products and support market entry strategies.

## Funding rounds

- Series B, Dec 19, 2024, $30M — Novo Holdings, Acorn Innovestments, Hartree Partners LP, Celesta Capital, Martin Marietta Materials Inc, 2150
- Series C, Feb 28, 2022, $65M — Novo Holdings, Hartree Partners LP, Celesta Capital, Martin Marietta Materials Inc, 2150

## Investors

- Novo Holdings — Series C, Series B
- Hartree Partners LP — Series C, Series B
- Celesta Capital (https://capitalatlas.ai/funds/celesta-capital) — Series C, Series B
- Martin Marietta Materials Inc — Series C, Series B
- 2150 (https://capitalatlas.ai/funds/2150) — Series C, Series B
- Acorn Innovestments (https://capitalatlas.ai/funds/acorn-innovestments) — Series B